Cancer Advances, Inc. Announces Issuance of New U.S. Patent
February 28, 2023 02:00 ET
|
Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
January 27, 2023 04:58 ET
|
Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Immune Checkpoint Inhibitors Clinical Trial Analysis 2022: Wide Variety of Clinical and Preclinical Research Currently Ongoing Bodes Well for Growth
December 15, 2022 05:18 ET
|
Research and Markets
Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors: Analysis of Clinical Trial Results (Featuring Recently Published Trial Results, Contemporary Pipeline Review, Clinical...
Immune Checkpoint Inhibitors Global Market Report 2022: Featuring Bristol-Myers Squibb, Merck, Novartis, Pfizer & More
November 29, 2022 08:08 ET
|
Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market, by Drug Class, By Cancer Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
September 06, 2022 07:45 ET
|
Aesther Healthcare Acquisition Corp.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol,...
Global Checkpoint Inhibitors Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F Featuring AstraZeneca, Bristol-Myers Squibb, Merck & Co, Roche, Pfizer, Incyte, Novartis, and NewLink Genetics
July 29, 2022 06:23 ET
|
Research and Markets
Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users" report has been added to ResearchAndMarkets.com's offering. ...
The Worldwide Metastatic Cancer Drug Industry is Expected to Reach $68.3 Billion by 2028
June 30, 2022 05:33 ET
|
Research and Markets
Dublin, June 30, 2022 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Cancer Type, Route of Administration, Drug Class,...
World Immune-checkpoint Drugs in Oncology Analytical Handbook 2022
June 08, 2022 03:18 ET
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immune-checkpoint Drugs in Oncology:...
Immuno-Oncology Drug Development Analytical Tool 2022: 1260 Companies/Partners Who are Developing 3,896 I-O Drugs Where of 2,948 are in Active Development in Cancer Across 629 Different Targets
May 26, 2022 06:28 ET
|
Research and Markets
Dublin, May 26, 2022 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drug Development: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immuno-Oncology Drug Development:...
2022 Oncolytic Virotherapies Analytical Tool: 85 Companies Who are Developing 150 Oncolytic Virus Drugs Where 113 are in Active Development in Cancer Across 40 Different Targets
May 11, 2022 07:03 ET
|
Research and Markets
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Oncolytic Virotherapies: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Oncolytic Virotherapies: Analytical Tool is the...